# Enliven Therapeutics, Inc.: Form 8-K, filed Jan 7, 2026

- Company: [Enliven Therapeutics, Inc.](/companies/elvn.md) (CIK 1672619)
- Form: 8-K
- Filed: 2026-01-07
- Accepted by EDGAR: Jan 7, 2026, 09:15 ET
- Period: 2026-01-06
- Accession: 0001193125-26-005535
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1672619/000119312526005535/d28332d8k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1672619/000119312526005535/

## Items reported

- Item 5.02: Departure or appointment of officers or directors
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1672619/000119312526005535/d28332d8k.htm

Filed Jan 7, 2026.
Source: SEC EDGAR, the filing index for accession 0001193125-26-005535. Last ingested by Listed: Nov 5, 2026, 17:49 ET. No prices; not investment advice.